{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:31:41Z","timestamp":1787225501116,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide and is closely linked to obesity, insulin resistance, type 2 diabetes, and dyslipidemia. It ranges from simple steatosis to steatohepatitis (metabolic dysfunction-associated steatohepatitis), which can progress to fibrosis, cirrhosis, or liver cancer. Beyond liver-related issues, MASLD is a systemic disease strongly associated with extrahepatic complications such as cardiovascular disease (CVD), chronic kidney disease (CKD), cancers, endocrine disorders, musculoskeletal problems, and sleep apnea. CVD and cancer are the leading causes of death in MASLD patients, with liver-related mortality ranking third. Fibrosis severity is the key predictor of overall and cause-specific mortality. MASLD significantly increases the risk and progression of type 2 diabetes, CVD, and CKD. It is also linked to increased risks of extrahepatic cancers, particularly colorectal, pancreatic, and breast cancers. Endocrine conditions such as hypothyroidism and polycystic ovary syndrome and musculoskeletal disorders, including sarcopenia and osteoporosis, frequently co-occur with MASLD. Obstructive sleep apnea independently contributes to the severity of liver disease and shares overlapping metabolic pathways. Surgical and transplant outcomes are worse in patients with MASLD due to impaired liver regeneration and increased postoperative risks. The recent approval of resmetirom offers a new therapeutic option, whereas lifestyle changes remain the cornerstone of management. Given the multisystemic impact of MASLD, a patient-centered approach is essential for effective treatment and improved long-term results. In this article, we provide an overview of key extrahepatic conditions commonly associated with MASLD and their clinical significance.<\/jats:p>","DOI":"10.4103\/tcmj.tcmj_158_25","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T21:00:16Z","timestamp":1753304416000},"page":"378-385","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Extrahepatic manifestations of metabolic dysfunction-associated steatotic liver disease: An updated clinical overview"],"prefix":"10.4103","volume":"37","author":[{"given":"Chia-Hsun","family":"Tsai","sequence":"first","affiliation":[{"name":"Center for Digestive Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hsing","family":"Hung","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuck-Siu","family":"Wong","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lu","family":"Hsu","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Hung","family":"Ko","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Chou","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Feng","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sou-Hsin","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"Department of Post-Acute Care Center, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"Department of Plastic Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Sheng","family":"Hsu","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"},{"name":"Department of Medical Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"},{"name":"Department of Plastic Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"R1-20251009","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R2-20251009","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD:A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"R3-20251009","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH:From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep"},{"key":"R4-20251009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","article-title":"Immunological mechanisms and therapeutic targets of fatty liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R5-20251009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-024-03889-x","article-title":"Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system:A review","volume":"99","author":"Svobodov\u00e1","year":"2025","journal-title":"Arch Toxicol"},{"key":"R6-20251009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/antiox14010056","article-title":"Gut microbiota at the crossroad of hepatic oxidative stress and MASLD","volume":"14","author":"Termite","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"R7-20251009","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease:A population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"R8-20251009","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"R9-20251009","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes:A meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"R10-20251009","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R11-20251009","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/jgh.14734","article-title":"Type 2 diabetes mellitus:A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease","volume":"34","author":"Tada","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-20251009","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"R13-20251009","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1038\/s41598-025-89293-6","article-title":"Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults","volume":"15","author":"Chung","year":"2025","journal-title":"Sci Rep"},{"key":"R14-20251009","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"R15-20251009","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease:A systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"R16-20251009","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"key":"R17-20251009","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/s41598-018-23014-0","article-title":"Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease:A cohort study","volume":"8","author":"Jang","year":"2018","journal-title":"Sci Rep"},{"key":"R18-20251009","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1053\/j.gastro.2019.06.026","article-title":"Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017","volume":"157","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"R19-20251009","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity \u2013A longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"R20-20251009","doi-asserted-by":"crossref","first-page":"e14276","DOI":"10.1111\/eci.14276","article-title":"Association of MASLD with the risk of extrahepatic cancers:A systematic review and meta-analysis of 18 cohort studies","volume":"54","author":"Zhou","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"R21-20251009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12978-018-0519-2","article-title":"A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease:An update meta-analysis","volume":"15","author":"Wu","year":"2018","journal-title":"Reprod Health"},{"key":"R22-20251009","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/liv.14279","article-title":"Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis","volume":"40","author":"Sarkar","year":"2020","journal-title":"Liver Int"},{"key":"R23-20251009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J Hepatol"},{"key":"R24-20251009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/HEP.0000000000001095","article-title":"Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease:An observational study","volume":"82","author":"Untalan","year":"2025","journal-title":"Hepatology"},{"key":"R25-20251009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20251009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00535-024-02184-x","article-title":"Liver fibrotic burden across the spectrum of hypothyroidism","volume":"60","author":"Du","year":"2025","journal-title":"J Gastroenterol"},{"key":"R27-20251009","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.20725","article-title":"Chronic liver injury during obstructive sleep apnea","volume":"41","author":"Tann\u00e9","year":"2005","journal-title":"Hepatology"},{"key":"R28-20251009","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11325-018-1625-7","article-title":"Association between obstructive sleep apnea and non-alcoholic fatty liver disease:A systematic review and meta-analysis","volume":"22","author":"Jin","year":"2018","journal-title":"Sleep Breath"},{"key":"R29-20251009","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41366-024-01493-8","article-title":"Obstructive sleep apnea (OSA) is associated with increased risk of early-onset sarcopenia and sarcopenic obesity:Results from NHANES 2015-2018","volume":"48","author":"Tao","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"R30-20251009","first-page":"1034","article-title":"Association between metabolic dysfunction-associated fatty liver disease and cognitive impairment","volume":"10","author":"Yu","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"R31-20251009","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/dom.16232","article-title":"Association of metabolic dysfunction-associated fatty liver disease with white matter hyperintensity and cognitive decline:A longitudinal cohort study","volume":"27","author":"Jung","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R32-20251009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13195-024-01498-5","article-title":"Association of MAFLD and MASLD with all-cause and cause-specific dementia:A prospective cohort study","volume":"16","author":"Bao","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R33-20251009","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ajkd.2023.08.016","article-title":"Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD","volume":"83","author":"Li","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"R34-20251009","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2011.04038.x","article-title":"Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease","volume":"75","author":"Pirgon","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R35-20251009","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2011-3010","article-title":"Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese","volume":"97","author":"Li","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-20251009","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.clnu.2024.04.034","article-title":"Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease:A cross-sectional study at a health examination center","volume":"43","author":"Yokoyama","year":"2024","journal-title":"Clin Nutr"},{"key":"R37-20251009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo","year":"2017","journal-title":"J Hepatol"},{"key":"R38-20251009","doi-asserted-by":"crossref","first-page":"101544","DOI":"10.1016\/j.aohep.2024.101544","article-title":"Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD):A systematic review and meta-analysis","volume":"29","author":"Malik","year":"2024","journal-title":"Ann Hepatol"},{"key":"R39-20251009","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD):A systematic review and meta-analysis","volume":"43","author":"Li","year":"2024","journal-title":"Clin Nutr"},{"key":"R40-20251009","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/jcsm.13543","article-title":"Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography","volume":"15","author":"Kim","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R41-20251009","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"R42-20251009","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1111\/ajd.13015","article-title":"Relationship between psoriasis and non-alcoholic fatty liver disease \u2013Updated systematic review and adjusted meta-analysis","volume":"60","author":"Phan","year":"2019","journal-title":"Australas J Dermatol"},{"key":"R43-20251009","doi-asserted-by":"crossref","first-page":"1400741","DOI":"10.3389\/fmed.2024.1400741","article-title":"Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis:A case-control study and serological comparison","volume":"11","author":"Lin","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R44-20251009","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1091-255X(98)80025-5","article-title":"Hepatic steatosis as a potential risk factor for major hepatic resection","volume":"2","author":"Behrns","year":"1998","journal-title":"J Gastrointest Surg"},{"key":"R45-20251009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/TP.0000000000002466","article-title":"Steatosis in liver transplantation:Current limitations and future strategies","volume":"103","author":"Linares","year":"2019","journal-title":"Transplantation"},{"key":"R46-20251009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cgh.2021.11.014","article-title":"Outcomes of nonalcoholic steatohepatitis after liver transplantation:An updated meta-analysis and systematic review","volume":"21","author":"Yong","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R47-20251009","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.transproceed.2021.02.025","article-title":"Liver-related and cardiovascular outcome of patients transplanted for nonalcoholic fatty liver disease:A European single-center study","volume":"53","author":"Van","year":"2021","journal-title":"Transplant Proc"},{"key":"R48-20251009","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s11605-023-05794-7","article-title":"Postoperative prognosis of non-alcoholic fatty liver disease-associated intrahepatic cholangiocarcinoma:A multi-center propensity score matching analysis","volume":"27","author":"Yu","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"R49-20251009","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"R50-20251009","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"R51-20251009","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists:An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"R52-20251009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/13543784.2023.2230115","article-title":"Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)","volume":"32","author":"Puengel","year":"2023","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_158_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:21Z","timestamp":1786724781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_158_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_158_25","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"2025-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}